

## Curriculum Vitae

### Personalia

Name: Saskia C.A. de Jager  
Email: s.c.a.dejager@umcutrecht.nl  
Date of birth: January 24<sup>th</sup> 1979  
Place of birth: Culemborg  
Nationality: Dutch



### Education:

2017 Base course regulation and organization of clinical research (BROK, Netherlands Federation of University Medical Centers)  
2010 SMWBO certified medical-biological researcher Immunology  
2004 - 2008 PhD, Leiden Academic Center for Drug Research, Div. of Biopharmaceutics and Therapeutic Gene Modulation. Title thesis: 'Chemokines in atherosclerotic lesion development and stability – from mice to man'. October 23<sup>th</sup>, 2008  
1996-2000 Degree in animal sciences (Hoger Laboratorium Onderwijs, Hogeschool van Utrecht)  
1996 Highschool graduation (HAVO, Koninging Wilhelmina College, Culemborg, the Netherlands)

### Academic Appointments:

Current Associate professor Laboratory of Experimental Cardiology, and Laboratory for Translational Immunology, University Medical Center, Utrecht, the Netherlands  
2014-2019 Assistant professor Laboratory of Experimental Cardiology, and Laboratory for Translational Immunology, University Medical Center, Utrecht, the Netherlands  
2013 - 2014 Post-doc Laboratory of Experimental Cardiology and Laboratory for Translational Immunology, University Medical Center, Utrecht, the Netherlands  
2008 - 2012 Post-doc Therapeutic Immunomodulation, Leiden Amsterdam Center for Drug Research, Leiden, the Netherlands  
2002 - 2004 Research Technician Biopharmaceutics, Leiden Amsterdam Center for Drug Research, Leiden University, the Netherlands  
2000 - 2002 Research Technician Pharmacology and Pathophysiology, Utrecht Institute for Pharmaceutical Science; Utrecht University, the Netherlands

### Summary of Research Field

Saskia de Jager, associate professor of Experimental Cardiology at the UMC Utrecht, is investigating the role of inflammation patients with chronic heart failure and aims at identifying potential drugs. Saskia started her career at Leiden University, where she used animal models to study inflammatory reactions in blood vessels and atherosclerosis. At the UMC Utrecht, she was able to switch gears to heart failure and translate her research into clinical practice. Saskia is best known for her work on cardiovascular immunology. She and her colleagues found that the two forms of chronic heart failure are characterized by different inflammatory responses. After an infarction, inflammatory cells infiltrate the heart to clean up the damage and in patients with chronic heart failure they never disappear completely. The lingering cells damage the heart muscle cells that are still healthy and the inflammation thereby contributes to the progression of the disease. Saskia's research is designed to find a better tailored therapy for patients with heart failure. She hopes that in time she will be able to make risk assessments for them based on inflammation profiles, who has a higher risk of rapid progression, and who does not?"

Since obtaining her PhD, Dr. de Jager has worked for more than 12 years on the problem of cardiovascular disease, leading to the publication of 90 articles. Her research has been funded by the

European Commission, the Dutch Heart foundation, the initiative CardioVascular Research Netherlands and the Dutch Cardiovascular Alliance.

### **Honours**

- 2018 Referee of the Year Award, Dutch Heart Foundation, 2018 (€1250 travel grant)
- 2016 Nominated for 'Supervisor of the Year' award, initiative of PhD students from the graduate school of life sciences
- 2004 fellowship Dutch Atherosclerosis Society meeting, the Netherlands, in recognition of an outstanding presentation and defense (Adventitial Mast Cell Degranulation Enhances the Incidence of Thrombotic Events in Atherosclerotic Plaques, €2000 travel grant)
- 2004 Young Investigators Award at the 10th Scandinavian Atherosclerosis Conference, Denmark for an outstanding scientific contribution to atherosclerosis research (Adventitial Mast Cell Degranulation Enhances the Incidence of Thrombotic Events in Atherosclerotic Plaques, DKR 1500.-).

### **Research Support**

- 2013: FP7 Athero-B-Cell - Targeting and exploiting B cell functions for treatment in cardiovascular disease, European Union. PI: (5.9MEur total budget).
- 2013: Queen of Hearts – Improving diagnosis of CVD in women, Dutch heart foundation, WP leader: (2.3MEur total budget).
- 2015: CVON RECONNECT - Renal connection to microvascular disease and heart failure with preserved ejection fraction, PI (5.0MEur total budget).
- 2016: NovaCare – A novel therapeutic antibody and companion diagnostic for non-ischemic cardiac remodeling, Eurostars, WP leader (2.2MEur total budget).
- 2017: More Knowledge with Fewer Animals, ZonMW, main applicant (3 grants, 30kEur total budget).
- 2018: Top-EV - Technology Of Protein delivery through Extracellular Vesicles to target PCSK9, Dutch heart foundation, Public Private Partnership, PI (0.5MEur total budget).
- 2019: CVON RACE-V proof of concept grant - Autoimmunity at the crossroad of coagulation and inflammation in Atrial Fibrillation, main applicant: (50kEur).
- 2020: Dutch PLN foundation – Inflammation in heart failure: is our immune system failing the PLN heart? Main applicant (50kEur).
- 2020: CVON preConnex bridge grant - GDF15 as a key regulator in the renal-cardiac connection: towards therapeutic intervention, main applicant (30kEur).
- 2021: DCVA IMPRESS - national collaborative knowledge platform to impact on sex- and gender sensitive cardiovascular medicine, PI (3MEur total budget)
- 2021: Early HFpEF young talent grant - Monocyte activation and trained Immunity in Heart Failure with preserved Ejection Fraction patients with high inflammatory risk profiles, supervising PI (40kEur)
- 2021: DCVA RECONNECT - Renal connection to microvascular disease and heart failure with preserved ejection fraction: the next phase, PI (3MEur total budget)

### **Patents**

- Future cardiac event biomarkers. Octrooinumber: WO2009034470

### **Collaborations with private partners:**

PEPperPRINT (Germany), epitope mapping, QVQ (NL), nanobodies, Visualsonics (Canada), high frequency ultrasound, Genesis Pharma (Greece), contract research, EnCare Biotech (NL), Eurostars Novacare, Firalis (France), Eurostars Novacare, Bering Limited (UK), FP7 Athero B Cell, Roche Innovation Center Copenhagen (RICC, Denmark)

## Management

Management of small animal facility including all work related to EU animal legislation. Currently supervising one postdoc, five technicians, three PhD students, and several bachelor and master students. Currently seven successfully completed PhD projects.

## Extracurricular activities

- Member ESC working group Atherosclerosis and Vascular Biology
- Associate editor Frontiers in Cardiovascular Medicine – Gender in Cardiovascular Medicine
- Member editorial board of Frontiers in Cardiovascular Medicine (section Vascular Medicine), Vascular Pharmacology, Atherosclerosis and Journal of Cardiovascular and Translational Research.
- Expert Reviewer for several scientific journals (i.e. Circulation, Circ Res., Arterioscler Thromb Vasc Biol, Eur Heart J, Cardiovasc Res, Plos, Sci Rep, Eur J Immunol, Vaccine) and research proposals (national and international).
- Member of review committee Animal Welfare body
- Fellow of the supervisory board of the University of Applied Sciences Utrecht

## Teaching/Mentoring:

Coordinator of 4 teaching courses: vascular biology (3th year bachelor biomedical sciences), cardiovascular immunology (capita selecta master biomedical sciences), sophisticated lab techniques and animal models (biannual PhD course). Mentor in BMW Academy bachelor Biomedical Sciences UU, UU Examiner for students performing internship abroad, Mentor within the young talent program of CVON Reconnect.

## Output indicators:

Total publications: 89

H-Index: 26

## Publication list:

1. van der Heijden CDCC, Smeets EMM, Aarntzen EHJG, Wesseling M, **de Jager SCA**, Rixen NP. Growth differentiation factor 15 levels are similar in primary aldosteronism and essential hypertension and do not predict arterial inflammation. *J Hypertens*. 2021 Mar 1;39(3):593-596. doi: 10.1097/HJH.0000000000002727.
2. Silvis MJM, Kaffka Genaamd Dengler SE, Odille CA, Mishra M, van der Kaaij NP, Doevendans PA, Sluijter JPG, de Kleijn DPV, **de Jager SCA**, Bosch L, van Hout GPJ. Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation: The Road to Translational Success. *Front Immunol*. 2020 Dec 8;11:599511. doi: 10.3389/fimmu.2020.599511. eCollection 2020.
3. Martins-Marques T, Ribeiro-Rodrigues T, **de Jager SC**, Zuzarte M, Ferreira C, Cruz P, Reis L, Baptista R, Gonçalves L, Sluijter JP, Girao H. Myocardial infarction affects Cx43 content of extracellular vesicles secreted by cardiomyocytes. *Life Sci Alliance*. 2020 Oct 23;3(12):e202000821. doi: 10.26508/lsa.202000821.
4. Depuydt MA, Prange KH, Slenders L, Örd T, Elbersen D, Boltjes A, **de Jager SC**, Asselbergs FW, de Borst GJ, Aavik E, Lönnberg T, Lutgens E, Glass CK, den Ruijter HM, Kaikkonen MU, Bot I, Slütter B, van der Laan SW, Yla-Herttuala S, Mokry M, Kuiper J, de Winther MP, Pasterkamp G. Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics. *Circ Res*. 2020 Sep 28. doi: 10.1161/CIRCRESAHA.120.316770.

5. **de Jager SCA**, Sluijter JPG. Current Perspectives on Inflammation in Cardiovascular Disease; from Biomarker to Therapy. *J Cardiovasc Transl Res.* 2021 Feb;14(1):1-2. doi: 10.1007/s12265-020-10070-z.
6. Demkes EJ, Rijken S, Szymanski MK, Hoefler IE, Sluijter JPG, **de Jager SCA**. Requirements for Proper Immunosuppressive Regimens to Limit Translational Failure of Cardiac Cell Therapy in Preclinical Large Animal Models. *J Cardiovasc Transl Res.* 2020 May 31. doi: 10.1007/s12265-020-10035-2.
7. Kessler EL, Oerlemans MIFJ, van den Hoogen P, Yap C, Sluijter JPG, **de Jager SCA**. Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives. *J Cardiovasc Transl Res.* 2020 May 22. doi: 10.1007/s12265-020-10026-3.
8. Wesseling M, de Poel JHC, **de Jager SCA**. Growth differentiation factor 15 in adverse cardiac remodeling: from biomarker to causal player. *ESC Heart Fail.* 2020 Aug;7(4):1488-1501. doi: 10.1002/ehf2.12728.
9. Nguyen ITN, Brandt MM, van de Wouw J, van Drie RWA, Wesseling M, Cramer MJ, **de Jager SCA**, Merkus D, Duncker DJ, Cheng C, Joles JA, Verhaar MC. Both male and female obese ZSF1 rats develop cardiac dysfunction in obesity-induced heart failure with preserved ejection fraction. *PLoS One.* 2020 May 6;15(5):e0232399.
10. Bosch L, de Haan JJ, Bastemeijer M, van der Burg J, van der Worp E, Wesseling M, Viola M, Odille C, El Azzouzi H, Pasterkamp G, Sluijter JPG, Wever KE, **de Jager SCA**. The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis. *Heart Fail Rev.* 2020 Apr 25. doi: 10.1007/s10741-020-09960-w.
11. Meeuwssen JAL, de Vries J, Zoet GA, Franx A, Fauser BCJM, Maas AHM, Velthuis BK, Appelman YE, Visseren FL, Pasterkamp G, Hoefler IE, van Rijn BB, den Ruijter HM, **de Jager SCA**. Circulating Neutrophils Do Not Predict Subclinical Coronary Artery Disease in Women with Former Preeclampsia. *Cells.* 2020 Feb 18;9(2):468. doi: 10.3390/cells9020468.
12. **de Jager SC**, Hoefler IE. Legumain in cardiovascular disease: Culprit or ally? *Atherosclerosis.* 2020 Mar;296:66-67. doi: 10.1016/j.atherosclerosis.2020.01.007.
13. Bosch L, de Haan JJ, Seijkens TTP, van Tiel CM, Brans MAD, Pasterkamp G, Lutgens E, **de Jager SCA**. The therapeutic potential of targeting CD40-TRAF6 pathway in cardiovascular Diseases. *Int J Cardiol.* 2020 Feb 1;300:220. doi: 10.1016/j.ijcard.2019.09.013.
14. van den Hoogen P, **de Jager SCA**, Mol EA, Schoneveld AS, Huibers MMH, Vink A, Doevendans PA, Laman JD, Sluijter JPG. Potential of mesenchymal- and cardiac progenitor cells for therapeutic targeting of B-cells and antibody responses in end-stage heart failure. *PLoS One.* 2019 Dec 31;14(12):e0227283. doi: 10.1371/journal.pone.0227283. eCollection 2019.

15. Hartman RJG, Korporaal SJA, Mokry M, **de Jager SCA**, Meeuwsen JAL, van der Laan SW, Lansu NR, Zoet GA, Pasterkamp G, Urbanus RT, Hoefler IE, Franx A, Velthuis BK, van Rijn BB, den Ruijter HM; Queen of Hearts and CREW consortia. Platelet RNA modules point to coronary calcification in asymptomatic women with former preeclampsia. *Atherosclerosis*. 2019 Dec;291:114-121. doi: 10.1016/j.atherosclerosis.2019.10.009.
16. Frodermann V, Rohde D, Courties G, Severe N, Schloss MJ, Amatullah H, McAlpine CS, Cremer S, Hoyer FF, Ji F, van Koevorden ID, Herisson F, Honold L, Masson GS, Zhang S, Grune J, Iwamoto Y, Schmidt SP, Wojtkiewicz GR, Lee IH, Gustafsson K, Pasterkamp G, **de Jager SCA**, Sadreyev RI, MacFadyen J, Libby P, Ridker P, Scadden DT, Naxerova K, Jeffrey KL, Swirski FK, Nahrendorf M. Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. *Nat Med*. 2019 Nov;25(11):1761-1771. doi: 10.1038/s41591-019-0633-x.
17. Fontaine MAC, Westra MM, Bot I, Jin H, Franssen AJPM, Bot M, **de Jager SCA**, Dzhagalov I, He YW, van Vlijmen BJM, Gijbels MJJ, Reutelingsperger CP, van Berkel TJC, Sluimer JC, Temmerman L, Biessen EAL. Low human and murine Mcl-1 expression leads to a pro-apoptotic plaque phenotype enriched in giant-cells. *Sci Rep*. 2019 Oct 10;9(1):14547.
18. van den Hoogen P, **de Jager SCA**, Huibers MMH, Schoneveld AH, Puspitasari YM, Valstar GB, Oerlemans MIFJ, de Weger RA, Doevendans PA, den Ruijter HM, Laman JD, Vink A, Sluijter JPG. Increased circulating IgG levels, myocardial immune cells and IgG deposits support a role for an immune response in pre- and end-stage heart failure. *J Cell Mol Med*. 2019 Nov;23(11):7505-7516.
19. **de Jager SCA**, Hoefler IE. Local inflammatory responses take their toll on the heart. *Int J Cardiol*. 2019 Oct 15;293:254-255.
20. Gremmels H, Teraa M, **de Jager SCA**, Pasterkamp G, de Borst GJ, Verhaar MC. A Pro-Inflammatory Biomarker-Profile Predicts Amputation-Free Survival in Patients with Severe Limb Ischemia *Sci Rep*. 2019 Jul 24;9(1):10740.
21. Meeuwsen JAL, de Vries JJ, van Duijvenvoorde A, van der Velden S, van der Laan SW, van Koevorden ID, van de Weg SM, de Borst GJ, de Winther MPJ, Kuiper J, Pasterkamp G, Hoefler IE, **de Jager SCA** ; Queen of Hearts Consortium. Circulating CD14<sup>+</sup>CD16<sup>+</sup>-classical monocytes do not associate with a vulnerable plaque phenotype, and do not predict secondary events in severe atherosclerotic patients. *J Mol Cell Cardiol*. 2019 Feb;127:260-269.
22. Bosch L, de Haan JJ, Seijkens TT, van Tiel CM, Brans MA, Pasterkamp G, Lutgens E, **de Jager SC**. Small molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failure. *Int J Cardiol*. 2019 Mar 15;279:141-144.

23. Siemelink MA, van der Laan SW, Haitjema S, van Koeverden ID, Schaap J, Wesseling M, **de Jager SCA**, Mokry M, van Iterson M, Dekkers KF, Luijk R, Foroughi Asl H, Michoel T, Björkegren JLM, Aavik E, Ylä-Herttuala S, de Borst GJ, Asselbergs FW, El Azzouzi H, den Ruijter HM, Heijmans BT, Pasterkamp G. Smoking is Associated to DNA Methylation in Atherosclerotic Carotid Lesions. *Circ Genom Precis Med*. 2018 Sep;11(9):e002030.
24. Hoefler IE, de Jager SCA. Janus revisited: The intricate role of the immune system in neovascularization. *Int J Cardiol*. 2018 Jun 1;260:193-194.
25. Wesseling M, Sakkars TR, **de Jager SCA**, Pasterkamp G, Goumans MJ. The morphological and molecular mechanisms of epithelial/endothelial-to-mesenchymal transition and its involvement in atherosclerosis. *Vascul Pharmacol*. 2018 Jul;106:1-8.
26. Maracle CX, Agca R, Helder B, Meeuwse JAL, Niessen HWM, Biessen EAL, de Winther MPJ, **de Jager SCA**, Nurmohamed MT, Tas SW. Noncanonical NF- $\kappa$ B signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction. *Atherosclerosis*. 2018 Mar;270:33-41.
27. van Puijvelde GHM, Foks AC, van Bochove RE, Bot I, Habets KLL, **de Jager SC**, Ter Borg MND, van Osch P, Boon L, Vos M, de Waard V, Kuiper J. CD1d deficiency inhibits the development of abdominal aortic aneurysms in LDL receptor deficient mice. *PLoS One*. 2018 Jan 18;13(1):e0190962.
28. Ellenbroek GHJM, de Haan JJ, van Klarenbosch BR, Brans MAD, van de Weg SM, Smeets MB, de Jong S, Arslan F, Timmers L, Goumans MTH, Hoefler IE, Doevendans PA, Pasterkamp G, Meyaard L, **de Jager SCA**. Leukocyte-Associated Immunoglobulin-like Receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice. *Sci Rep*. 2017 Dec 21;7(1):18039.
29. de Haan JJ, Bosch L, Borgman A, Bastemeijer M, Brans MAD, van de Weg SM, de Kleijn DPV, Sluijter JPG, El Azzouzi H, **de Jager SCA**. Complement 5a Receptor deficiency does not influence adverse cardiac remodeling after pressure-overload in mice. *Sci Rep*. 2017 Dec 6;7(1):17045.
30. **de Jager SCA**, Hoefler IE. Beyond the matrix: MMP2 as critical regulator of inflammation-mediated vascular dysfunction. *Cardiovasc Res*. 2017 Dec 1;113(14):1705-1707.
31. Wesseling M, van Koeverden ID, van Lammeren GW, van der Laan SW, Haitjema S, de Vries JPM, den Ruijter HM, **de Jager SCA**, Hoefler I, Blankestijn P, Verhaar M, de Kleijn DPV, de Borst GJ, Pasterkamp G. Impaired kidney function is associated with intraplaque hemorrhage in patients undergoing carotid endarterectomy. *Atherosclerosis*. 2017 Nov;266:128-135.

32. **de Jager SCA**, Meeuwssen JAL, van Pijpen FM, Zoet GA, Barendrecht AD, Franx A, Pasterkamp G, van Rijn BB, Goumans MJ, den Ruijter HM. Preeclampsia and coronary plaque erosion: Manifestations of endothelial dysfunction resulting in cardiovascular events in women. *Eur J Pharmacol.* 2017 Dec 5;816:129-137.
33. Meeuwssen JAL, van Duijvenvoorde A, Gohar A, Kozma MO, van de Weg SM, Gijsberts CM, Haitjema S, Björkbacka H, Fredrikson GN, de Borst GJ, den Ruijter HM, Pasterkamp G, Binder CJ, Hoefler IE, **de Jager SCA**. High Levels of (Un)Switched Memory B Cells Are Associated With Better Outcome in Patients With Advanced Atherosclerotic Disease. *J Am Heart Assoc.* 2017 Sep 7;6(9). pii: e005747.
34. De Haan JJ, Haitjema S, den Ruijter HM, Pasterkamp G, de Borst GJ, Teraa M, Verhaar MC, Gremmels H, **de Jager SCA**. Growth Differentiation Factor 15 Is Associated With Major Amputation and Mortality in Patients With Peripheral Artery Disease. *J Am Heart Assoc.* 2017 Aug 30;6(9). pii: e006225.
35. Wang JW, Fontes MSC, Wang X, Chong SY, Kessler EL, Zhang YN, de Haan JJ, Arslan F, **de Jager SCA**, Timmers L, van Veen TAB, Lam CSP, Kleijn DPV. Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload. *Sci Rep.* 2017 Aug 23;7(1):9193.
36. Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, **de Jager SC**, Urbanus RT, Hoefler IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. *Cancer Cell.* 2017 Aug 14;32(2):238-252.e9.
37. Meeuwssen JAL, Wesseling M, Hoefler IE, **de Jager SCA**. Prognostic Value of Circulating Inflammatory Cells in Patients with Stable and Acute Coronary Artery Disease. *Front Cardiovasc Med.* 2017 Jul 14;4:44.
38. Haitjema S, Kofink D, van Setten J, van der Laan SW, Schoneveld AH, Eales J, Tomaszewski M, **de Jager SCA**, Pasterkamp G, Asselbergs FW, den Ruijter HM. Loss of Y Chromosome in Blood Is Associated With Major Cardiovascular Events During Follow-Up in Men After Carotid Endarterectomy. *Circ Cardiovasc Genet.* 2017 Aug;10(4):e001544.

39. Gohar A, Gonçalves I, Vrijenhoek J, Haitjema S, van Koeverden I, Nilsson J, de Borst GJ, de Vries JP, Pasterkamp G, den Ruijter HM, Björkbacka H, **de Jager SCA**. Circulating GDF-15 levels predict future secondary manifestations of cardiovascular disease explicitly in women but not men with atherosclerosis. *Int J Cardiol*. 2017 Aug 15;241:430-436.
40. Ellenbroek GHJM, van Hout GPJ, **de Jager SCA**, Timmers L, Vink A, Goldschmeding R, van der Kraak P, Pasterkamp G, Hoefler IE, Doevendans PA, Appelman Y. Radiofrequency Ablation of the Atherosclerotic Plaque: a Proof of Concept Study in an Atherosclerotic Model. *J Cardiovasc Transl Res*. 2017 Apr;10(2):221-232.
41. Nossent AY, Bastiaansen AJ, Peters EA, de Vries MR, Aref Z, Welten SM, **de Jager SC**, van der Pouw Kraan TC, Quax PH. CCR7-CCL19/CCL21 Axis is Essential for Effective Arteriogenesis in a Murine Model of Hindlimb Ischemia. *J Am Heart Assoc*. 2017 Mar 8;6(3). pii: e005281.
42. Haitjema S, van Setten J, Eales J, van der Laan SW, Gandin I, de Vries JP, de Borst GJ, Pasterkamp G, Asselbergs FW, Charchar FJ, Wilson JF, **de Jager SC**, Tomaszewski M, den Ruijter HM. Genetic variation within the Y chromosome is not associated with histological characteristics of the atherosclerotic carotid artery or aneurysmal wall. *Atherosclerosis*. 2017 Apr;259:114-119.
43. Ellenbroek GH, van Puijvelde GH, Anas AA, Bot M, Asbach M, Schoneveld A, van Santbrink PJ, Foks AC, Timmers L, Doevendans PA, Pasterkamp G, Hoefler IE, van der Poll T, Kuiper J, **de Jager SC**. Leukocyte TLR5 deficiency inhibits atherosclerosis by reduced macrophage recruitment and defective T-cell responsiveness. *Sci Rep*. 2017 Feb 16;7:42688.
44. Joffre J, Potteaux S, Zeboudj L, Loyer X, Boufenzler A, Laurans L, Esposito B, Vandestienne M, **de Jager SC**, Hénique C, Zlatanova I, Taleb S, Bruneval P, Tedgui A, Mallat Z, Gibot S, Ait-Oufella H. Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis. *J Am Coll Cardiol*. 2016 Dec 27;68(25):2776-2793.
45. van Hout GP, Bosch L, Ellenbroek GH, de Haan JJ, van Solinge WW, Cooper MA, Arslan F, **de Jager SC**, Robertson AA, Pasterkamp G, Hoefler IE. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. *Eur Heart J*. 2017 Mar 14;38(11):828-836.
46. Pasterkamp G, van der Laan SW, Haitjema S, Foroughi Asl H, Siemelink MA, Bezemer T, van Setten J, Dichgans M, Malik R, Worrall BB, Schunkert H, Samani NJ, de Kleijn DP, Markus HS, Hoefler IE, Michoel T, **de Jager SC**, Björkegren JL, den Ruijter HM, Asselbergs FW. Human Validation of Genes Associated With a Murine Atherosclerotic Phenotype. *Arterioscler Thromb Vasc Biol*. 2016 Jun;36(6):1240-6.



47. **De Jager SC**, Pasterkamp G. Atheroprotective properties of human Omentin-1 in experimental atherosclerosis. *Cardiovasc Res.* 2016 May 1;110(1):1-3.
48. Frodermann V, van Duijn J, van Puijvelde GH, van Santbrink PJ, Lagraauw HM, de Vries MR, Quax PH, Bot I, Foks AC, **de Jager SC**, Kuiper J. Heat-killed *Staphylococcus aureus* reduces atherosclerosis by inducing anti-inflammatory macrophages. *J Intern Med.* 2016 Jun;279(6):592-605..
49. Frodermann V, van Duijn J, van Pel M, van Santbrink PJ, Bot I, Kuiper J, **de Jager SC**. Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development. *Sci Rep.* 2015 Oct 22;5:15559.
50. van Hout GP, van Solinge WW, Gijsberts CM, Teuben MP, Leliefeld PH, Heeres M, Nijhoff F, de Jong S, Bosch L, **de Jager SC**, Huisman A, Stella PR, Pasterkamp G, Koenderman LJ, Hoefler IE. Elevated mean neutrophil volume represents altered neutrophil composition and reflects damage after myocardial infarction. *Basic Res Cardiol.* 2015 Nov;110(6):58.
51. de Hoog VC, Bovens SM, **de Jager SC**, van Middelaar BJ, van Duijvenvoorde A, Doevendans PA, Pasterkamp G, de Kleijn DP, Timmers L. BLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia-reperfusion injury. *Cardiovasc Res.* 2015 Dec 1;108(3):367-76.
52. van Hout GP, Teuben MP, Heeres M, de Maat S, de Jong R, Maas C, Kouwenberg LH, Koenderman L, van Solinge WW, **de Jager SC**, Pasterkamp G, Hoefler IE. Invasive surgery reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction. *J Cell Mol Med.* 2015 Nov;19(11):2655-63.
53. Wezel A, Lagraauw HM, van der Velden D, **de Jager SC**, Quax PH, Kuiper J, Bot I. Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression. *Atherosclerosis.* 2015 Aug;241(2):289-96.
54. Frodermann V, van Puijvelde GH, Wierds L, Lagraauw HM, Foks AC, van Santbrink PJ, Bot I, Kuiper J, **de Jager SC**. Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a novel therapy for atherosclerosis. *J Immunol.* 2015 Mar 1;194(5):2208-18.
55. den Ruijter HM, Pasterkamp G, **de Jager SC**. Adiponectin regulation in cardiovascular disease: is diseased fat showing its true color? *Arterioscler Thromb Vasc Biol.* 2014 Oct;34(10):2180-1.
56. De Hoog VC, Timmers L, Van Duijvenvoorde A, **De Jager SC**, Van Middelaar BJ, Smeets MB, Woodruff TM, Doevendans PA, Pasterkamp G, Hack CE, De Kleijn DP. Leucocyte expression of

complement C5a receptors exacerbates infarct size after myocardial reperfusion injury. *Cardiovasc Res.* 2014 Sep 1;103(4):521-9.

57. Maiwald S, Sivapalaratnam S, Motazacker MM, van Capelleveen JC, Bot I, **de Jager SC**, van Eck M, Jolley J, Kuiper J, Stephens J, Albers CA, Vosmeer CR, Kruize H, Geerke DP, van der Wal AC, van der Loos CM, Kastelein JJ, Trip MD, Ouwehand WH, Dallinga-Thie GM, Hovingh GK. Mutation in KERA identified by linkage analysis and targeted resequencing in a pedigree with premature atherosclerosis. *PLoS One.* 2014 May 30;9(5):e98289.
58. Bot I, Daissormont IT, Zerneck A, van Puijvelde GH, Kramp B, **de Jager SC**, Sluimer JC, Manca M, Hérias V, Westra MM, Bot M, van Santbrink PJ, van Berkel TJ, Su L, Skjelland M, Gullestad L, Kuiper J, Halvorsen B, Aukrust P, Koenen RR, Weber C, Biessen EA. CXCR4 blockade induces atherosclerosis by affecting neutrophil function. *J Mol Cell Cardiol.* 2014 Sep;74:44-52.
59. Willems S, van der Velden D, Quax PH, de Borst GJ, de Vries JP, Moll FL, Kuiper J, Toes RE, **de Jager SC**, de Kleijn DP, Hoefler IE, Pasterkamp G, Bot I. Circulating immunoglobulins are not associated with intraplaque mast cell number and other vulnerable plaque characteristics in patients with carotid artery stenosis. *PLoS One.* 2014 Feb 21;9(2):e88984.
60. Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, Jawad AH, Shiri-Sverdlov R, Bot I, **de Jager SC**, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PC. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. *Br J Pharmacol.* 2014 Feb;171(3):723-34.
61. van den Akker F, **de Jager SC**, Sluijter JP. Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. *Mediators Inflamm.* 2013;2013:181020..
62. Rensing KL, **de Jager SC**, Stroes ES, Vos M, Twickler MT, Dallinga-Thie GM, de Vries CJ, Kuiper J, Bot I, von der Thüsen JH. Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice. *Cardiovasc Res.* 2014 Feb 1;101(2):277-87..
63. Karper JC, **de Jager SC**, Ewing MM, de Vries MR, Bot I, van Santbrink PJ, Redeker A, Mallat Z, Binder CJ, Arens R, Jukema JW, Kuiper J, Quax PH. An unexpected intriguing effect of Toll-like receptor regulator RP105 (CD180) on atherosclerosis formation with alterations on B-cell activation. *Arterioscler Thromb Vasc Biol.* 2013 Dec;33(12):2810-7.
64. Foks AC, Ran IA, Wasserman L, Frodermann V, Ter Borg MN, **de Jager SC**, van Santbrink PJ, Yagita H, Akiba H, Bot I, Kuiper J, van Puijvelde GH. T-cell immunoglobulin and mucin domain

3 acts as a negative regulator of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2013 Nov;33(11):2558-65.

65. **de Jager SC**, Pasterkamp G. Crosstalk of lipids and inflammation in atherosclerosis: the PRO of PGRN? *Cardiovasc Res.* 2013 Oct 1;100(1):4-6.
66. Karper JC, Ewing MM, de Vries MR, **de Jager SC**, Peters EA, de Boer HC, van Zonneveld AJ, Kuiper J, Huizinga EG, Brondijk TH, Jukema JW, Quax PH. TLR accessory molecule RP105 (CD180) is involved in post-interventional vascular remodeling and soluble RP105 modulates neointima formation. *PLoS One.* 2013 Jul 2;8(7):e67923..
67. Bot M, Van Veldhoven PP, **de Jager SC**, Johnson J, Nijstad N, Van Santbrink PJ, Westra MM, Van Der Hoeven G, Gijbels MJ, Müller-Tidow C, Varga G, Tietge UJ, Kuiper J, Van Berkel TJ, Nofer JR, Bot I, Biessen EA. Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient mice. *PLoS One.* 2013 May 20;8(5):e63360..
68. Bot M, **de Jager SC**, MacAleese L, Lagrauw HM, van Berkel TJ, Quax PH, Kuiper J, Heeren RM, Biessen EA, Bot I. Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation. *J Lipid Res.* 2013 May;54(5):1265-74. \*
69. **de Jager SC**, Bot I, Kraaijeveld AO, Korporaal SJ, Bot M, van Santbrink PJ, van Berkel TJ, Kuiper J, Biessen EA. Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. *Arterioscler Thromb Vasc Biol.* 2013 Mar;33(3):e75-83.
70. Foks AC, Bot I, Frodermann V, **de Jager SC**, Ter Borg M, van Santbrink PJ, Yagita H, Kuiper J, van Puijvelde GH. Interference of the CD30-CD30L pathway reduces atherosclerosis development. *Arterioscler Thromb Vasc Biol.* 2012 Dec;32(12):2862-8.
71. Otten JJ, **de Jager SC**, Kavelaars A, Seijkens T, Bot I, Wijnants E, Beckers L, Westra MM, Bot M, Busch M, Bermudez B, van Berkel TJ, Heijnen CJ, Biessen EA. Hematopoietic G-protein-coupled receptor kinase 2 deficiency decreases atherosclerotic lesion formation in LDL receptor-knockout mice. *FASEB J.* 2013 Jan;27(1):265-76.
72. **de Jager SC**, Bongaerts BW, Weber M, Kraaijeveld AO, Rousch M, Dimmeler S, van Diejen-Visser MP, Cleutjens KB, Nelemans PJ, van Berkel TJ, Biessen EA. Chemokines CCL3/MIP1 $\alpha$ , CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes. *PLoS One.* 2012;7(9):e45804.
73. **de Jager SC**, Kuiper J. Vaccination strategies in atherosclerosis. *Thromb Haemost.* 2011 Nov;106(5):796-803.

74. **de Jager SC**, Bermúdez B, Bot I, Koenen RR, Bot M, Kavelaars A, de Waard V, Heijnen CJ, Muriana FJ, Weber C, van Berkel TJ, Kuiper J, Lee SJ, Abia R, Biessen EA. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. *J Exp Med*. 2011 Feb 14;208(2):217-25.
75. de Waard V, Bot I, **de Jager SC**, Talib S, Egashira K, de Vries MR, Quax PH, Biessen EA, van Berkel TJ. Systemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differently. *Atherosclerosis*. 2010 Jul;211(1):84-9.
76. Bot I, **de Jager SC**, Bot M, van Heiningen SH, de Groot P, Veldhuizen RW, van Berkel TJ, von der Thüsen JH, Biessen EA. The neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis. *Circ Res*. 2010 Jan 8;106(1):89-92.
77. **de Jager SC**, Canté-Barrett K, Bot I, Husberg C, van Puijvelde GH, van Santbrink PJ, Yndestad A, van den Oever JM, Kuiper J, van Berkel TJ, Lipp M, Zwaginga JJ, Fibbe WE, Aukrust P, Biessen EA. Impaired effector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient bone marrow transplant chimeras. *Transplantation*. 2009 Sep 15;88(5):631-9.
78. Ye D, Kraaijeveld AO, Grauss RW, Willems SM, van Vark-van der Zee LC, **de Jager SC**, Jauhainen M, Kuivenhoven JA, Dallinga-Thie GM, Atsma DE, Hogendoorn PC, Biessen EA, Van Berkel TJ, Jukema JW, van Eck M. Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes. *J Intern Med*. 2008 Dec;264(6):571-85.
79. **de Jager SC**, Kraaijeveld AO, Grauss RW, de Jager W, Liem SS, van der Hoeven BL, Prakken BJ, Putter H, van Berkel TJ, Atsma DE, Schaliij MJ, Jukema JW, Biessen EA. CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. *J Mol Cell Cardiol*. 2008 Sep;45(3):446-52.
80. van Wanrooij EJ, **de Jager SC**, van Es T, de Vos P, Birch HL, Owen DA, Watson RJ, Biessen EA, Chapman GA, van Berkel TJ, Kuiper J. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. *Arterioscler Thromb Vasc Biol*. 2008 Feb;28(2):251-7.
81. Kraaijeveld AO, **de Jager SC**, de Jager WJ, Prakken BJ, McColl SR, Haspels I, Putter H, van Berkel TJ, Nagelkerken L, Jukema JW, Biessen EA. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. *Circulation*. 2007 Oct 23;116(17):1931-41.

82. Bot I, **de Jager SC**, Zerneck A, Lindstedt KA, van Berkel TJ, Weber C, Biessen EA. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. *Circulation*. 2007 May 15;115(19):2516-25. Epub 2007 Apr 30.
83. Kraaijeveld AO, **de Jager SC**, van Berkel TJ, Biessen EA, Jukema JW. Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? *Curr Pharm Des*. 2007;13(10):1039-52.
84. Lucerna M, Zerneck A, de Nooijer R, **de Jager SC**, Bot I, van der Lans C, Kholova I, Liehn EA, van Berkel TJ, Yla-Herttuala S, Weber C, Biessen EA. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. *Blood*. 2007 Jan 1;109(1):122-9.
85. Dekker RJ, van Thienen JV, Rohlena J, **de Jager SC**, Elderkamp YW, Seppen J, de Vries CJ, Biessen EA, van Berkel TJ, Pannekoek H, Horrevoets AJ. Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. *Am J Pathol*. 2005 Aug;167(2):609-18.
86. Out R, Hoekstra M, **de Jager SC**, de Vos P, van der Westhuyzen DR, Webb NR, Van Eck M, Biessen EA, Van Berkel TJ. Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice. *J Lipid Res*. 2005 Jun;46(6):1172-81.
87. Bot I, von der Thüsen JH, Donners MM, Lucas A, Fekkes ML, **de Jager SC**, Kuiper J, Daemen MJ, van Berkel TJ, Heeneman S, Biessen EA. Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE<sup>-/-</sup>-mice. *Circ Res*. 2003 Sep 5;93(5):464-71.
88. van Houwelingen AH, Kool M, **de Jager SC**, Redegeld FA, van Heuven-Nolsen D, Kraneveld AD, Nijkamp FP. Mast cell-derived TNF-alpha primes sensory nerve endings in a pulmonary hypersensitivity reaction. *J Immunol*. 2002 May 15;168(10):5297-302.
89. van Houwelingen AH, **de Jager SC**, Kool M, van Heuven-Nolsen D, Kraneveld AD, Nijkamp FP. Hypersensitivity reactions in mouse airways after a single and a repeated hapten challenge. *Inflamm Res*. 2002 Feb;51(2):63-8.